###### Strengths and limitations of this study

-   To reduce selection bias, all the studies were independently reviewed and risk of bias was assessed by two authors and disagreements solved by including a third reviewer.

-   One limitation of this systematic review is that the included studies were recruiting only adult patients.

-   Inclusion of single-arm studies could be a potential limitation as these can cause bias in the systematic review.

-   To reach a broad scope for the systematic review three databases, MEDLINE, Embase and CENTRAL, were searched.

-   The systematic review was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Introduction {#s1}
============

In spite of novel immunosuppressive regimens and antimicrobial prophylaxis, infectious complications remain a threat for solid organ and stem cell transplant (SCT) recipients.[@R1] These patients are especially susceptible to opportunistic infections like cytomegalovirus (CMV), *Pneumocystis jirovecii* pneumonia (PCP), febrile neutropoenia, human herpesvirus 6 (HHV-6) and invasive fungal infections (IFI).[@R1] Graft failure is a major risk of these opportunistic infections.[@R6] In recent years, organ transplantation and immunosuppressive regimes have developed greatly and thus become available for a wider patient population. This requires adequate antimicrobial prophylaxis guidelines and studies supporting the scientific evidence.

Antimicrobial prophylaxis and pre-emptive therapy are used as preventive measures; however, these vary notably among different transplant centres.[@R9] This can be explained by differences in local setting and lack of high level evidence in antifungal, antimicrobial and antiviral prophylaxis guidelines and fairly dated evidence for some infections like PCP and febrile neutropenia.[@R5] Although prophylaxis has proven to be a beneficial strategy, breakthrough infections and adverse events resulting in discontinuation of prophylaxis occur.[@R15] The rates of failure of prophylaxis have remained around 10%--20% for opportunistic infections.[@R15] In order to be able to optimise prophylaxis, it is important to understand underlying causes for failure. This systematic review will identify (1) causes of failure of prophylactic treatment, (2) factors that might contribute to failure of prophylaxis and (3) different approaches for administering prophylaxis.

This systematic review aimed to summarise the main reasons why prophylaxis and pre-emptive therapy has failed in solid organ and allogeneic SCT recipients and how failure is reported in prospective studies. In this review, we focus on failure of prophylactic therapy, during the treatment window.

Methods {#s2}
=======

Definition of failure {#s2-1}
---------------------

In this systematic review, we have defined *failure of prophylaxis and pre-emptive therapy* as stopping or changing the therapy during the study period for any stated reason. For example, failure could be a breakthrough infection, non-adherence, adverse events leading to stopping of therapy, etc. Even if some of the side effects could be anticipated, if this leads to stopping of therapy, it was defined as failure. We did not look into infections in the postprophylactic period.

Search strategy and selection criteria {#s2-2}
--------------------------------------

Methods of the analysis and inclusion criteria were specified in advance and documented in a protocol, which is available online: <https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=77606> ([online supplementary appendix 1](#SP1){ref-type="supplementary-material"}). This report follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist ([online supplementary appendix 2](#SP1){ref-type="supplementary-material"}).[@R21] This systematic review included prospective randomised controlled trials (RCT) and prospective single-arm studies from 1 January 2010 to 1 October 2018. The starting date was 1 January 2010 due to the changes in management of different infections in recent decades and to include the most recent evidence.[@R11] There were no limitations for the patient setting, publication status and language. We analysed the failure during prophylaxis and pre-emptive therapy, thus the follow-up time varied. The review included patients (16 years and older) who had received either allogeneic stem cell, lung, kidney, liver, heart, pancreas or small bowel transplantation. Studies done on children under 16 years were not included as this would have introduced more variability and require a separate analysis, thus were out with the scope of this review. Moreover, these patients were receiving trimethoprim/sulfamethoxazole for prophylaxis of PCP, ciprofloxacin for prophylaxis of febrile neutropenia, ganciclovir and/or valganciclovir for prophylaxis or pre-emptive-therapy of CMV and human herpesvirus 6 (HHV-6); or posaconazole or voriconazole or fluconazole or itraconazole for prophylaxis of invasive fungal infections (IFI). Primary outcome measures were breakthrough infections, adverse events leading to stopping of treatment, switching medication or dose reduction. Secondary outcome measures were acquired resistance to antimicrobials, antifungals or antivirals and death.
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To identify studies for this systematic review, the following databases were searched: MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL). The search was performed on 1 October 2018. The search strategy included MeSH terms and variations of transplant types, medications and prophylaxis ('Antibiotic Prophylaxis' (Mesh) OR antimicrobial OR antimicrobial) AND (Host OR Transplants OR Transplantation OR Transplant Recipients OR immunocompromised OR transplant\* OR kidney transplant\*). The full-search strategies of all databases can be found in [online supplementary appendix 3](#SP1){ref-type="supplementary-material"}. The searches were done by AGM and MB. For screening, we used Covidence software ([www.covidence.org](www.covidence.org)).

The literature search and data extraction for inclusion and eligibility for this systematic review were done according to the inclusion criteria by AGM and MB independently. If there were discrepancies between the results, these were discussed and resolved with JWA or with consensus. If there was data missing or additional questions from the selected studies, then the authors of these studies were contacted. We excluded conference proceedings, retrospective studies, reviews, editorials and letters to the editor.

Outcomes, data extraction and quality {#s2-3}
-------------------------------------

Data were extracted by AGM and independently checked by MB. Disagreement between reviewers was resolved by discussion with a third reviewer JWA. Data were extracted from each included trial on: characteristics of patients, type of intervention, study design, study population, outcome measurement, reasons for failure of prophylaxis or pre-emptive therapy (stopping of prophylaxis/pre-emptive therapy), main conclusions by authors, strengths and limitations ([online supplementary appendix 4](#SP1){ref-type="supplementary-material"}).

We considered performing a meta-analysis for our systematic review, however because the patient cohorts include different transplantations and varied interventions, the studies were too heterogeneous, we decided to do a qualitative systematic review. The studies were divided into CMV and IFI prophylaxis and pre-emptive treatment groups.

Risk of bias in individual studies was assessed independently by AGM and MB. For assessing bias in individual studies, Revised Cochrane risk-of-bias tool for randomised trials (RoB 2) was used for RCTs and Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) was used for prospective single-arm studies.[@R22]

Results {#s3}
=======

The search identified 3317 records for inclusion in the review. In total, 603 duplicate records were removed, and 2543 records were excluded after screening of title and abstract. Full-text screening of 171 articles resulted in 24 studies (in 30 articles) (PRISMA flow diagram in [figure 1](#F1){ref-type="fig"}) to be included in the final review. We decided to exclude one full text in Japanese as it would not likely change the outcome of our systematic review. We contacted corresponding authors of 24 studies (30 articles) for further information about reasons for preliminary stopping of prophylaxis and overall adherence to treatment, seven responded and three of those sent prespecified protocols; however, none provided additional information about failure of prophylaxis or pre-emptive treatment. The individual study characteristics and risk of bias are presented in [table 1](#T1){ref-type="table"}.

![PRISMA diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.+++](bmjopen-2019-034940f01){#F1}

###### 

Study characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                     Country                                                                                               Study design   Population                                                                  Pre-emptive therapy/ prophylaxis      Prophylaxis/ pre-emptive medication   Comparison                                      Sample size    Duration                                        Follow-up                   Summary assessment of risk of bias
  ------------------------------------------------ ----------------------------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------- ------------------------------------- ------------------------------------- ----------------------------------------------- -------------- ----------------------------------------------- --------------------------- ------------------------------------
  CYTOMEGALVIRUS PROPHYLAXIS/PRE-EMPTIVE THERAPY                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Humar *et al*,** **2010[@R15]**                Australia, Belgium, Canada, Brazil, France, Germany, the UK, Italy, Poland, Romania, Spain, the USA   RCT            Kidney transplant recipients aged 17--77 years                              Prophylaxis                           Valganciclovir                        Valganciclovir different duration and placebo   320 patients   100 and 200 days                                12 months                   Low risk

  **Halim *et al*, 2016** [@R31]\                  Kuwait, Egypt                                                                                         RCT            Kidney transplant recipients with mean age of 42.4 years                    Prophylaxis                           Valganciclovir                        Valganciclovir different duration               201 patients   98.1 days (mean)                                12 months                   Some concerns
  **Ghei th *et al*, 2017** [@R32]                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Witzke *et al,* 2012[@R33], 2018[@R34]**       Germany, Austria                                                                                      RCT            Kidney transplant recipients with mean age of 52.7 years                    Prophylaxis and pre-emptive therapy   Valganciclovir                        Valganciclovir as pre-emptive treatment         296 patients   100 days (14 days pre-emptive until 100 days)   7 years                     Some concerns

  **Reischig *et al,* 2012** [@R35]                Czeck Republic                                                                                        RCT            Kidney transplant recipients with mean age of 49 years                      Prophylaxis and pre-emptive therapy   Valganciclovir                        Valacyclovir                                    70 patients    3 months                                        2 years                     Some concerns

  **Reischig *et al*, 2015[@R36]**                 Czeck Republic                                                                                        RCT            Kidney transplant recipients with mean age of 49 years                      Prophylaxis                           Valganciclovir                        Valacyclovir                                    119 patients   3 months                                        1 year                      Some concerns

  **Togashi *et al,* 2011** [@R38]                 Japan                                                                                                 RCT            Liver transplant recipients with mean age of 52.1 years                     Pre-emptive therapy                   Valganciclovir                        Ganciclovir                                     22 patients    2 weeks                                         1 year                      Some concerns

  **Padulles *et al,* 2016** [@R25]                Spain                                                                                                 RCT            Kidney, liver and heart transplant recipients with mean age of 53.9 years   Prophylaxis and treatment             Valganciclovir/\                      Valganciclovir/ganciclovir different dosing     53 patients    NA (not reported)                               6 months                    Low risk
                                                                                                                                                                                                                                                                                          ganciclovir                                                                                                                                                                      

  **Palmer *et al,* 2010,**\                       USA                                                                                                   RCT            Lung transplant recipients with median age of 55.5 years                    Prophylaxis                           Valganciclovir                        Placebo                                         136 patients   12 months                                       3.9 years (mean)            Some concerns
  **Finlen Copeland *et al,* 2011** [@R26]                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Chawla *et al,* 2011[@R28]**                   USA                                                                                                   RCT            Allogeneic transplant recipients aged 18--64                                Pre-emptive therapy                   Valganciclovir                        Ganciclovir                                     37 patients    28 days                                         4 weeks                     High risk

  **Boeckh *et al,* 2015** [@R29]                  USA                                                                                                   RCT            Allogeneic transplant recipients aged 16--70                                Pre-emptive therapy                   Valganciclovir                        Placebo                                         184 patients   150/120 days valganciclovir/ placebo(medians)   640 days                    Some concerns

  **Kim *et al,* 2010** [@R30]                     South Korea                                                                                           RCT            Allogeneic transplant recipients aged 16--49                                Pre-emptive therapy                   Ganciclovir                           Ganciclovir different dosing                    68 patients    14 days (median)                                42 months (median)          Some concerns

  **Montejo *et al,* 2010** [@R39]                 Spain                                                                                                 Single-arm     Kidney transplant recipients with median age 47 years                       Prophylaxis                           Valganciclovir                        NA                                              34 patients    3 months                                        1 year                      Critical risk

  **Nanmoku *et al,* 2018** [@R40]                 Japan                                                                                                 Single-arm     Kidney transplant recipients with mean age 48.7 years                       Prophylaxis                           Valganciclovir                        NA                                              100 patients   6 months                                        1 year                      Serious risk

  **Perrottet *et al,* 2009**\                     France                                                                                                Single-arm     Kidney, heart, lung, liver transplant recipients aged 18--70                Prophylaxis                           Valganciclovir and\                   NA                                              65 patients    3 months                                        1 year                      Serious risk
  **Manuel *et al*, 2010** [@R9]                                                                                                                                                                                                                                                          ganciclovir                                                                                                                                                                      

  **McGillicuddy *et al,* 2010**                   USA                                                                                                   Single-arm     Kidney and pancreas transplant recipients mean age 53.5 years               Pre-emptive therapy and prophylaxis   Valganciclovir/ ganciclovir           Valganciclovir/\                                130 patients   90 days                                         1 year                      Serious risk
                                                                                                                                                                                                                                                                                                                                ganciclovir pre-emptive therapy                                                                                                            

  **Takenaka *et al,* 2012** [@R45]                Japan                                                                                                 Single-arm     Allogeneic transplant recipients aged 25--68                                Pre-emptive therapy                   Valganciclovir                        NA                                              20 patients    2 weeks                                         10 weeks                    Serious risk

  **Park *et al,* 2012** [@R46]                    South Korea                                                                                           Single-arm     Allogeneic transplant recipients aged 16--70                                Pre-emptive therapy                   Ganciclovir                           Ganciclovir different dosing                    97 patients    14 days (median)                                Not same for all patients   Moderate risk

  INVASIVE FUNGAL INFECTION PROPHYLAXIS                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Perrella *et al,* 2012** [@R47]                Italy                                                                                                 RCT            Liver transplant recipients (age NI)                                        Prophylaxis                           Fluconazole                           Amphotericin B                                  43 patients    7--14 days                                      1 year                      Some concerns

  **Winston *et al,* 2014** [@R17]                 USA                                                                                                   RCT            Liver transplant recipients aged 19--75 years                               Prophylaxis                           Fluconazole                           Anidulafungin                                   200 patients   21 days (median)                                90 days                     Low risk

  **Chaftari *et al,* 2012** [@R48]                USA                                                                                                   RCT            Allogeneic transplant recipients aged 20--69                                Prophylaxis                           Posaconazole                          Amphothericin B lipid complex                   40 patients    6 weeks                                         2 weeks                     Some concerns

  **Huang *et al,* 2012** [@R19]                   China                                                                                                 RCT            Allogeneic and autologous transplant recipients with mean age 32.7 years    Prophylaxis                           Itraconazole                          Micafungin                                      228 patients   42 days                                         4 weeks                     Some concerns

  **Park *et al,* 2016** [@R49]                    South Korea                                                                                           RCT            Allogeneic and autologous transplant recipients aged 20--64                 Prophylaxis                           Fluconazole                           Micafungin                                      250 patients   21 days                                         100 days                    Some concerns

  **Mitsani *et al,* 2012** [@R43]                 USA                                                                                                   Single-arm     Lung transplant recipients aged 20--74 years                                Prophylaxis                           Voriconazole                          NA                                              93 patients    3 months                                        NI                          Moderate risk

  **Cordonnier *et al,* 2010** [@R44]              France, Spain, Belgium, UK, Germany, Switzerland, Portugal, Sweden                                    Single-arm     Allogeneic transplant recipients aged 22--72 years                          Prophylaxis                           Voriconazole                          NA                                              45 patients    94 days (median)                                1 year                      Critical risk
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Summary assessment of risk of bias grades for:

RCTs using RoB tool:

Low risk of bias: The study is judged to be at low risk of bias for all domains for this result.

Some concerns: The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.

High risk of bias: The study is judged to be at high risk of bias in at least one domain for this result.

Single-arm prospective studies using ROBINS tool:.

Low risk of bias: The study is judged to be at low risk of bias for all domains.

Moderate risk of bias: The study is judged to be at low or moderate risk of bias for all domains.

Serious risk of bias: The study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.

Critical risk of bias: The study is judged to be at critical risk of bias in at least one domain.

NA, not applicable; NI, no information; RCT, randomised controlled trial.

We identified 24 studies including 2851 patients. Seventeen studies (11 RCTs[@R15] and six single-arm[@R39]) with 1952 subjects focused on CMV prophylaxis and seven studies (5 RCTs[@R17] and 2 single-arm[@R43]) with 899 subjects focused on IFI prophylaxis.

Of the 17 CMV studies, eight included only valganciclovir, two only ganciclovir, five included both valganciclovir and ganciclovir, two valaciclovir and valganciclovir. From all 17 CMV studies, seven focused only on prophylaxis, six only on pre-emptive therapy, three both on prophylaxis and pre-emptive therapy and one on prophylaxis and therapy.

The IFI studies varied with regard to study medication and patient group. Three studies evaluated fluconazole (comparison amphotericin B, anidulafungin and micafungin), one posaconazole (comparison amphotericin B lipid complex), one itraconazole (comparison micafungin) and two single-arm studies had voriconazole as study medication.

Failure of prophylaxis and pre-emptive therapy {#s3-1}
----------------------------------------------

No specific information about failure during prophylaxis or pre-emptive therapy was given in 25% (six studies: four being RCTs) of the included studies.[@R19] Four of these studies did record follow-up infections or long-term failure of prophylaxis therapy after cessation of prophylaxis[@R19] and for one RCT the time-point was not specified.[@R46]

The most common reasons for failure of CMV prophylaxis (1524 study subjects) and CMV pre-emptive therapy (428 study subjects) were adverse events[@R15] and breakthrough CMV.[@R15] For IFI prophylaxis (899 study subjects), it was adverse events[@R19] and IFI.[@R17] Overall, the adverse events and breakthrough infections were described in 54% (13 studies) and 38% (9 studies) of the studies respectively. In [table 2](#T2){ref-type="table"}, the reasons for stopping prophylaxis are described in detail. The detailed information about failure in the CMV (1506 study subjects) and IFI (761 study subjects) RCT groups are summarised in [figures 2 and 3](#F2 F3){ref-type="fig"}.

![Failure of CMV prophylaxis and pre-emptive therapy in 11 RCTs (y-axis represents the proportion of the transplant group in percentages and x-axis represents transplant). CMV, cytomegalovirus; RCTs, randomised controlled trials.](bmjopen-2019-034940f02){#F2}

![Failure of IFI prophylaxis in five RCTs (y-axis represents the proportion of the transplant group in percentages and x-axis represents transplant). For one study, 15% of failure was caused by patients discharged early, this has not been included in this figure. IFI, invasive fungal infection.](bmjopen-2019-034940f03){#F3}

###### 

Reasons for stopping prophylaxis or pre-emptive therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytomegalovirus prophylaxis/pre-emptive therapy                                                                                                                                                       
  ----------------------------------------------------------------------- ------------ ------------------------ ------------ ----------- ------------------ --------------------------------- --------- -----------------------
  **Study**                                                               AE           Breakthrough infection   Graft loss   Death       Patient decision   Physician/investigator decision   Other     Total number subjects

  Humar *et al*, 2010[@R15]                                               27 (8%)      51 (16%)                                          11 (3%)                                              14 (4%)   320

  Halim *et al*, 2016[@R31]                                                                                     2 (1%)       1 (0.5%)                                                                   201

  Reischig *et al*, 2012[@R35]                                                                                  10 (14%)     2 (3%)                                                                     70

  Reischig *et al*, 2015[@R36] ^1^                                        13 (11%)                              4 (3%)       3 (2.5%)                                                                   119

  Padulles *et al*, 2016[@R25]                                            1 (2%)                                                                                                                        53

  Palmer *et al*, 2010[@R27]                                              17 (12.5%)                                         7 (5%)      3 (2%)             15 (11%)                          3 (2%)    136

  Boeckh *et al*, 2015[@R29]                                              44 (24%)     35 (19%)                                                             20 (11%)                                    184

  Kim *et al*, 2010[@R30]                                                 1 (1.5%)                                           2 (3%)                                                                     68

  Montejo *et al*, 2010[@R39]                                                          3 (9%)                                                                                                           34

  Perrottet *et al*, 2009[@R41]                                                        3 (viremia)                                                                                                      65

  McGillicuddy *et al*, 2010[@R42]                                        3 (2%)       1 (1%)\                                                                                                          130
                                                                                       (^2^)                                                                                                            

  Park *et al*, 2012[@R49] ^3^                                            8 (8%)       6 (6%)                                37 (38%)                                                                   97

  **Invasive fungal infection prophylaxis**                                                                                                                                                             

  Winston *et al*, 2014[@R17] ^4^\                                                     2 (2%)                                1 (1%)                         2 (2%)                                      100 (fluconazole)\
  Fluconazole                                                                                                                                                                                           200 (total)

  Chaftari *et al*, 2012[@R48]\                                           8 (38%)                                                                                                                       21 (posaconazole)\
  Posaconazole                                                                                                                                                                                          40 (total)

  Huang *et al*, 2012[@R19]\                                              29 (20%)     12 (8%)                               1 (1%)                         4 (3%)                                      147 (itraconazole)\
  Itraconazole                                                                                                                                                                                          228 (total)

  Park *et al*, 2016[@R49]\                                               2 (2%)       3 (3%)                                                               3 (3%)                                      89 (fluconazole)\
  Fluconazole                                                                                                                                                                                           250 (total)

  Mitsani *et al*, 2012[@R43]                                             25 (27%)                                                                                                                      93

  Cordonnier *et al*, 2010[@R44]                                          2 (4%)       3\* (7%)                              11\* (2%)                                                                  45

  **NI in the following trials (timepoints not specified)**                                                                                                                                             

  Nanmoku *et al,* 2018[@R40]                                                                                                                                                                 100       

  Chawla *et al,* 2011[@R28]                                                                                                                                                                  37        

  Witzke *et al,* 2012[@R33]                                                                                                                                                                  296       

  Perrella *et al*, 2012[@R47]                                                                                                                                                                43        

  **All patients completed treatment protocol in the following trials**                                                                                                                                 

  Togashi *et al*, 2011[@R38]                                                          22                                                                                                               

  Takenaka *et al*, 2012[@R45]                                                         20                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1\. One patient moved to another country.

2\. No information on breakthrough infections during prophylaxis.

3\. 12 patients had dosage reductions.

4\. 36 patients were preliminarily stopped due to discharge from hospital.

\*Time-point not confirmed.

AE, adverse event; CMV, cytomegalovirus; IFI, invasive fungal infection; NI, no information (not reported).

From the secondary outcomes, death was reported more frequently---in 33% (n=8) of the studies, death was the reason for failure.[@R17] The secondary outcome resistance to antimicrobials, antivirals and antifungals was addressed in the introductions and discussions of the included studies, however not regarded as failure of therapy. Moreover, the presence and/or measurement of resistance to the study drug was described in two studies.[@R27] Boeckh *et al* report no resistance genes in the investigated patients and Palmer *et al* report one patient with known resistance to ganciclovir.

Not all identified cases of failure could be clarified even after contact with the authors of the studies. The reasons for stopping prophylaxis and pre-emptive therapy, *patient reasons* or *physician or sponsor decision*,[@R27] were not explained in any of these studies. Moreover, in two studies,[@R24] it was stated that prophylaxis was stopped because of *other* reasons. Adverse events, breakthrough infections and cause of death were mostly described in further detail in the included studies.[@R15] However, reasons 'other',[@R15] physician/investigator decision[@R17] and patients discretion[@R15] were grouped together in studies and not described in detail.

### Risk of bias across studies {#s3-1-1}

Risk of bias was assessed using five domains for RCTs: randomisation, assignment and adherence to intervention, measurement of outcome, missing data and selection of the reported results. For single-arm/observational studies domains were used: confounding, selection of participants, classification of interventions, missing data, measurement of outcomes and selection of the reported result. We concluded that all 16 RCTs and six single-arm had low risk of bias, three had some concerns and two had high risk of bias. Risk of bias in RCTs and single-arm studies is presented in [tables 3 and 4](#T3 T4){ref-type="table"}.

###### 

Risk of bias in RCTs using RoB tool

                                 Randomisation process   Assignment of intervention   Adhering to intervention   Measurement of outcomes   Missing outcome data   Selection of the reported result
  ------------------------------ ----------------------- ---------------------------- -------------------------- ------------------------- ---------------------- ----------------------------------
  Humar *et al,* 2010[@R15]      \+                      \+                           \+                         \+                        \+                     ?
  Halim *et al,* 2016[@R31]      ?                       \+                           \+                         ?                         \+                     ?
  Witzke *et al,* 2012[@R33]     \+                      \+                           \+                         ?                         \+                     ?
  Reischig *et al,* 2012[@R35]   \+                      \+                           \+                         ?                         \+                     ?
  Reischig *et al,* 2015[@R36]   \+                      \+                           \+                         ?                         \+                     ?
  Togashi *et al,* 2011[@R38]    ?                       \+                           \+                         ?                         \+                     ?
  Padulles *et al,* 2016[@R25]   \+                      \+                           \+                         \+                        \+                     ?
  Palmer *et al,* 2010[@R27]     \+                      \+                           ?                          \+                        \+                     ?
  Chawla *et al,* 2011[@R28]     ?                       ?                            ?                          ?                         \+                     ?
  Boeckh *et al,* 2015[@R29]     \+                      \+                           ?                          \+                        \+                     ?
  Kim *et al,* 2010[@R30]        ?                       \+                           \*+                        ?                         \+                     ?
  Perrella *et al,* 2012[@R47]   ?                       ?                            ?                          ?                         \+                     ?
  Winston *et al,* 2014[@R17]    \+                      \+                           \+                         \+                        \+                     ?
  Chaftari *et al,* 2012[@R48]   \+                      ?                            ?                          ?                         \+                     ?
  Huang *et al,* 2012[@R19]      \+                      \+                           ?                          ?                         \+                     ?
  Park *et al,* 2016[@R49]       ?                       \+                           \+                         ?                         \+                     ?

+low risk; ?, some concerns.

RCT, randomised controlled trials; RoB, risk-of-bias.

###### 

Risk of bias in single-arm studies using ROBINs tool

                                     Confounding   Selection of participants   Classification of interventions   Deviations from intended interventions   Missing data   Measurement of outcomes   Selection of the reported result
  ---------------------------------- ------------- --------------------------- --------------------------------- ---------------------------------------- -------------- ------------------------- ----------------------------------
  Montejo *et al,* 2010[@R39]        --            ?                           \+                                NI                                       --             ?                         NI
  Nanmoku *et al,* 2018[@R40]        \*            \+                          \+                                \+                                       \+             ?                         NI
  Perrottett *et al,* 2009[@R41]     \*            ?                           \+                                ?                                        \*             ?                         NI
  McGillicuddy *et al,* 2010[@R42]   \*            \+                          \+                                \*                                       \*             ?                         NI
  Takenaka *et al,* 2012[@R45]       \*            ?                           \+                                ?                                        \*             ?                         NI
  Park *et al*, 2012[@R46]           ?             \+                          \+                                ?                                        \+             ?                         NI
  Mitsani *et al*, 2012[@R43]        \*            ?                           \+                                ?                                        ?              ?                         NI
  Cordonnier *et al,* 2010[@R44]     \*            \*                          \+                                ?                                        ?              ?                         NI

+, low risk; ?, moderate risk; \*, serious risk; -, critical risk.

NI, no information; ROBINS, Risk of Bias in Non-randomised Studies of Interventions.

Discussion {#s4}
==========

We aimed to explore the reasons why prophylaxis and pre-emptive therapy failed in transplant recipients. Twenty-four studies were included into this systematic review. We concluded that the main reason for stopping prophylaxis was adverse events for both CMV and IFI prophylaxis and CMV pre-emptive therapy. We did not observe notable differences between the prophylaxis and pre-emptive therapy groups. This result was expected as cessation of ganciclovir therapy is often described due to debilitating side-effects, especially bone marrow suppression,[@R15] which is even more problematic in haematological patients.[@R28] Different antifungal agents have a diverse safety profile. Our results were also in line with the common side-effects of antifungals as we observed nausea and vomiting in azoles and nephrotoxicity in Amphotericin B as reasons for discontinuation of therapy.[@R43]

Adverse events are known to be under-reported so the numbers that we summarised in this systematic review might be underestimated.[@R51] A review by Golder *et al* [@R52] looked into different study designs and reporting of adverse events. The authors outlined that there is wide under-reporting of adverse events across different study designs and even more in the unpublished data. Unfortunately, contacting the authors of the studies included in this systematic review did not result in additional information about the reported adverse events. Meta-analysis was not done as the studies were too heterogeneous.

Surprisingly, reporting of failure was insufficient in 25% of RCTs and 50% of prospective single-arm studies. One-fourth of the studies did not report on preliminarily cessation of prophylaxis nor underlying reason. More worrisome was the fact that discontinuation of prophylaxis was mostly explained as adverse events and breakthrough infections, while patient and physicians' discretion as reasons were grouped together. On the other hand, we observed that only five studies did record infections that occurred after the prophylaxis had been stopped. This is concerning, as in a clinical setting and in developing guidelines, it is important to make a distinction of breakthrough infections during and after prophylaxis and pre-emptive therapy.[@R53] Also, it makes it more difficult to compare the efficacy of different medications, for example when using ganciclovir and letermovir.[@R53] Furthermore, one of the included RCTs[@R17] reported early discharge from hospital as the main argument for stopping of prophylaxis. In addition, some reasons were not clarified, for example physician and patient discretion were combined in two of the included studies. A systematic review published in 2018 explored the efficacy and safety of CMV prophylaxis; adverse events and breakthrough infections were addressed, however the authors did not explicitly report additional information why patients stopped within these studies.[@R54] Similarly, in a PCP prophylaxis systematic review, the authors described adverse events as reason for discontinuation while not mentioning adherence, resistance or patients' choice.[@R14]

A systematic review about quality of reporting RCTs in medical oncology described that 79% of the adverse events in studies are reported according to Consolidated Standards of Reporting Trials (CONSORT) criteria, although the description of participants and preliminary stopping in each stage of the study was done correctly in only 59% of the studies.[@R55] It has been argued that perhaps, poor reporting is deliberate to mask the shortcomings in study design.[@R55] One may expect that in a prospective study, the patients are recruited and analysed prospectively thus the data about failure of prophylaxis like adverse events should be readily obtainable. Thus, registering study protocols in clinical trial registers and following reporting guidelines helps consistent and more straightforward reporting of results.[@R57] Goldacre and colleagues have looked into reporting of clinical trials specifically with regard to outcomes. They concluded that most of the studies did not have sufficient reporting---either outcomes were added or prespecified outcomes were not reported.[@R59] These results raise concern to also whether failure is reported as per protocol. In our case, we faced a substantial quantity of missing data on failure and it is not always clear to us how studies were conducted with respect to exclusion of patients. An additional statement to the CONSORT criteria regarding better reporting of harms in randomised trials is a useful guidance document to improve conduct of studies and address shortcomings.[@R60]

According to our search criteria, we also planned to include studies looking into prophylaxis and pre-emptive therapy of PCP, HHV-6 virus and febrile neutropenia. Surprisingly, we were not able to identify suitable studies looking into prophylaxis of these infections for our systematic review. Current guidelines for the treatment of these infections use case reports, retrospective studies, surveillance studies and outdated literature to give recommendations.[@R5] For instance, a systematic review focusing on PCP prophylaxis in non-HIV immunocompromised patients is used as main guidance of prophylaxis in this patient group; the studies included in this review date back from 1974 to 2008 (13 in the range 1977--1990).[@R14] Moreover, the prophylaxis of febrile neutropenia is widely supported by a systematic review that included studies with quinolones published from 1980 to 2010 (10 in the range 1980--1997).[@R13] Half of the studies in these reviews were published more than 20 years ago. Certainly, the evidence from these reviews are relevant to the field; however, the landscape of treatment of transplant recipients has changed---notably, with the emergence of resistant pathogens[@R63] and new data in today's setting is needed to aid the update of clinical guidelines.[@R62]

As mentioned before, detailed data about failure of prophylaxis and pre-emptive therapy were lacking in some studies and no additional information was obtained when reaching out to the authors. Furthermore, a limitation of our study was the restriction of start date (1 January 2010). This was done to avoid the effect of the significant change in management of infections and focus on the most recent evidence.[@R11] Another limitation is that we did not include studies about children. On the other hand, included studies already showed a heterogeneous variety of patient populations (eg, autologous and allogeneic SCT recipients),[@R19] various types of infections and prophylaxis and pre-emptive therapy studies; therefore, we believe that adding paediatric studies would have further increased variability of our results.

There remains a variety of different practices between centres complicating patient transfers between hospitals.[@R9] We believe that having information about the discontinuation of failure of prophylaxis and pre-emptive therapy could provide valuable information for guideline committees, medical practitioners and researchers conducting studies with these medications. Without this information, similar errors could be repeated in different studies.

There are several ways to predict failure in a clinical setting. Detecting adverse events and avoiding breakthrough infections can be done by approaching the patient or treating the physician. For example, using mobile applications for reporting adverse events,[@R68] defining the high-risk patients[@R69] and therapeutic drug monitoring of potentially toxic medications.[@R71]

In [figure 4](#F4){ref-type="fig"}, we have summarised guidance on how to detect failure early.[@R68] As mentioned above, there are multiple studies that do not report the true breakthrough infections, only postprophylaxis infections are reported. In addition, we believe that defining the potential adverse events before and describing the method of measurement of these could increase adherence. Other supporting background from the current systematic review for this figure is presented in [Appendix 5](#SP1){ref-type="supplementary-material"}.

![Detecting failure in a clinical setting. AE, adverse event.](bmjopen-2019-034940f04){#F4}

Conclusions {#s4-1}
-----------

In general, RCTs and prospective single-arm studies about prophylaxis and pre-emptive therapy of opportunistic infections should provide more in-depth information about failure. The main reason why prophylaxis or pre-emptive therapy is stopped are adverse events; however, these may well be underreported. Thus, the management and reporting of adverse events is critically important and should be improved in clinical studies. In addition, our results suggest partially biased approach in the publication of clinical studies and therefore there are insufficient data to support evidence-based decision-making in prophylaxis of PCP, HHV-6 and febrile neutropenia.
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